Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that it has reached an agreement with the U.S. Department of Justice to resolve civil claims regarding the marketing of MYCAMINE® (micafungin sodium) for injection.
Copenhagen, 2014-04-17 20:58 CEST (GLOBE NEWSWIRE) -
ALK today announced that the US Food and Drug Administration (FDA) has approved the Biologic License Application (BLA) for RAGWITEK
Global pharmaceutical contract developer and manufacturer Aesica reports that it has introduced serialization services and begun commercial production of two anti-allergy product lines for the Chinese market at its Pianezza site, Italy, for a global, multinational client. The implementation took under six months to complete, with the first production of serialization batches just commenced, the company reports.
LifePack Forum Inc. will host a healthcare product packaging seminar and exhibitor showcase May 6 & 7, 2014, in Suzhou, China at the Suzhou Marriott Hotel, Gusu District. The event seeks to help solve the challenges faced by packaging professionals in China, show organizers report.
Sponsored by Eastman Chemical Company and Steripack, the event will cover the following topics:
The Healthcare Compliance Packaging Council (HCPC) announced the winners of its annual Compliance Package of the Year competition at RxAdherence 2014. The annual competition celebrates package innovations designed to improve patient adherence.
This year’s winners are:
• 2013 Compliance Package of the Year: Noven Therapeutics Brisdelle in MWV Dosepak from PCI (Packaging Coordinators, Inc)
• Compliance Package of the Year First Runner Up: Depomed Gralise Starter Pack from PCI
Package usability was a distinct theme at HealthPack this year. Not only did attendees get to hear the “voice of the customer” during the event’s annual nurses panel, but also a few speakers urged attendees to examine the end-user experience when designing medical device packaging.
Earlier syringe development may cut time-to-market, increase clinical trial appeal
Vetter, a leading contract development and manufacturing organization (CDMO), introduced two clinical syringe packages that make it easier to start syringe development earlier in the drug development process. Starting syringe work earlier, in full or partial parallel with vial development, can cut up to 18 months off time-to-market.